Buy Crypto
Pay with
USD
USD
Buy & Sell
Hot
Supports Visa, Mastercard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Markets
Trade
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Stocks
CFD
Stock CFD Derivatives
US Stocks
Access real US stocks and ETFs
HK Stocks
Trade quality Hong Kong-listed stocks
Korean Stocks
SK Hynix
Real Korean stocks and top assets
Stock Futures
High leverage, 24/7 trading
Tokenized Stocks
Backed by real stock assets
IPO Access
Unlock full access to global stock IPOs
GUSD
3.8%
Mint GUSD for Treasury RWA yields
Stocks Activities
Trade Popular Stocks and Unlock Generous Airdrops
Earn
Launch
CandyDrop
tag
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
tag
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investment
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
More
Promotions
AI
Others
IPO
2026 World Cup
Rewards
Square
Latest
Hot
News
Profile

《Large Institution》Goldman Sachs: Kelun-Biotech (06990.HK) sac-TMT combination therapy clinical study reaches primary endpoints, maintains a “Buy” rating

GasGuzzler
robot
Abstract generation in progress
Goldman Sachs issued a report saying that Kelun-Biotech (06990.HK) +32.800 (+6.584%) saw short selling of $99.4 million; the ratio was 16.011%. It announced an antibody-drug conjugate (ADC) targeting trophoblast cell-surface antigen 2 (TROP2)—luntsuc-TMT (sac-TMT, also known as SKB264/MK-2870)—in combination with Merck & Co.’s anti-PD-1 monoclonal antibody “Keytruda”, and that the Phase 3 clinical study (OptiTROP-Lung06) in first-line treatment of locally advanced or metastatic NSCLC with PD-L1 negativity has met its primary endpoint. The firm expected that the positive clinical results are a key step for sac-TMT in the 1L NSCLC study, raising the success rate of Lung06 from 81% to 90%; the success rate for the overseas 1L NSCLC indication with PD-L1 tumor proportion score (TPS) <50% was raised from 54% to 63%. Goldman Sachs raised its earnings per share forecasts for Kelun-Biotech for 2027 and 2028 to RMB 7.51 and RMB 14.46, respectively. The target price was raised from 561.4 to 582.95, maintaining a “Buy” rating, and believes Kelun-Biotech could become an influential global ADC drug company. (gc/u)(Hong Kong stock quotes are delayed by at least fifteen minutes. Short selling data is as of 2026-07-15 12:25.)
GS9.13%
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments

  • Pinned

Sitemap